TOCA - Tocagen: Targeting High-Grade Glioma
Tocagen (TOCA) has a drug in phase 3 trial targeting high grade glioma or HGG. This trial will yield results by the end of 2019. Past early stage trials have shown interesting efficacy data in this difficult to treat cancer. HGG, which includes both stage III gliomas as well as the extremely difficult to treat stage IV glioma known as glioblastoma ((GBM)) has very few and quite inadequate treatment options at present, and any progress in this field is always exciting, especially coming from such a small company.
The mechanism here is very